Big Deal: GV exits Flatiron Health · Articles · Global Corporate Venturing
GCV Asia Congress 2018
Skip Content

19 February 2018

Big Deal: GV exits Flatiron Health

Roche has agreed to acquire oncology research platform Flatiron in a deal that valued it at $2.15bn, giving GV what would be its fifth latest life sciences exit since the start of November.

Author: Robert Lavine, News Editor

US-based oncology research technology provider Flatiron Health is set to become the latest of GV’s life sciences-focused portfolio companies to net it an exit, after agreeing to a $1.9bn acquisition by pharmaceutical firm Roche last week.